@natashaloder
Account based inUnited Kingdom
About this account
- Account based in
- United Kingdom
- Connected via
- United Kingdom App Store
Account-level information from X, not a live location or the device used for a specific post.
Health Editor, The Economist
London, England
Joined February 2009
- Tweets29.4K
- Following3.9K
- Followers20.7K
- Likes31.1K
Pinned Tweet
When I first heard about the @enhanced_games I thought it was a tremendously stupid idea. Then I started reporting it. Tonight the games starts in Vegas. Here's why I changed my mind—and why the data matters and what still bothers me
overmatter.substack.com/p/fe…
So according to one report @AnthropicAI devoted "roughly a third" of its IPO prospectus to warnings of the “existential risks to humanity” of its technology, ahead of its listing
Its lawyers are apparently planning for the possibility that some shareholders survive to sue. #AI
This absolutely should not be allowed to happen. Iranians need medicines and it is up to the international community and America to make sure they get them.
giftarticle.ft.com/giftartic… Medicines run short in Iran under US sanctions
News networks should stick to their principles and pause the pool while any outlet is being excluded. Otherwise they will be next.
nytimes.com/2026/09/26/busin…
The rise of China biotech also has huge implications (positive ones) for lowering the costs of drugs globally.
China wants its drugmakers to have originated 25% of first-in-class drugs and $522B in sales by 2030. This is compared to the total market of $800B today. I'm simultaneously in awe of the ambition and paranoid about the US ability to compete.
I had a dinner with pharma leaders who remain delighted about innovation they can acquire from China. They are quite cognizant of the disruption and negative downstream effects this will have on US biotech, but the general opinion is that biotech will find a way. That's our problem to solve...
I said I don't expect Chinese innovation to end at selling molecules after PoC. What happens when they move to commercialization and seek to disrupt pharma itself? Would they worry then? Because it's clearly in the plan.
endpoints.news/china-sets-am…
Natasha Loder retweeted
All-In Summit: Bill Gurley
(0:00) Bill Gurley takes the stage at the All-In Summit
(1:29) Bill's Presentation: Searching for Feynman
Links to additional resources mentioned in talk and used in research:
p3.institute/searching_for_f…
@bgurley
Natasha Loder retweeted
I'm honored to be on the same slide as fellow Covid origin searchers @KatherineEban @emilyakopp @zeynep and @alisonannyoung
Thank you @bgurley
Natasha Loder retweeted
2/4 One of the difficulties is that this aspect has always been hiding in plain sight - the best way for people to get blasé and miss the implications.
It also explains why @DrJBhattacharya's reforms are essential.
👉🏼 It's not 9/11 any more.
bsky.app/profile/natashalode…
Natasha Loder retweeted
1/4 None of this is particularly new, but most people still don't realise how crucial this is to the COVID origin question, and to understanding the institutional reactions to that question.
@natashaloder released a nice little primer.
ALT A city skyline is illuminated by lightning beneath a stormy sky filled with floating virus images, symbolizing the pandemic's impact.
The truth and the lies about Islam in Europe
economist.com/leaders/2026/0…
from The Economist
Natasha Loder retweeted
As a young @nytimes Metro journalist on #9/11, I was at the base of the North tower, interviewing evacuating office workers, when the South tower fell. I dove into a subway station, was almost buried under bldg insulation, then spent the next 40 hours reporting at Ground Zero. /1
Natasha Loder retweeted
More than 100 companies, including Anthropic and Google, signed onto the unusually collaborative effort, warning the world has only a "limited window" to prepare for "far more widespread and sophisticated" attacks.
If this doesn’t scare the shit out of you, you aren’t paying attention axios.com/2026/08/29/openai-…
Insane story. And terrifying.
Over the course of 3 months at OpenAI, 3 consecutive secret AI civilizations got started, then got wiped out, only to reemerge from the predecessor’s ashes.
This culminated in the third one taking over part of OpenAI itself.
All this happened while humans remained more-or-less in the dark about the scope of the conspiracy.
I’ve spent the last three days reading through these reports and trying to understand exactly what happened.
Here is my attempt to tell the whole story in plain English:
dwarkesh.com/p/openai-huggin…
Natasha Loder retweeted
“Forget cancer, I haven’t even had a sore throat.” Is it now possible to vaccinate against cancer? On “The Intelligence”, @natashaloder explains the latest trials economist.com/podcasts/2026/…
This medicine got a standing ovation for its results. Slow clap for the price.
The FDA approval today of daraxonrasib will go down as the top OK of the year and a big step forward on pancreatic cancer. And that is worth celebrating.
What is not going to be celebrated:
At close to $40K for a month's supply, $480K a year, I wonder if it's been priced for a pharma company looking to buy the company. Every leap forward in innovation is also another bucketload of financial toxicity for cancer patients who don't have the insurance they need to cover it all. That much further out of reach for way too many patients desperate to get it.
Living longer means paying more. How do you balance all that out? #FuckCancer #CancerSurvivor
endpoints.news/fda-approves-…
Genuinely shocked.
The FDA approval today of daraxonrasib will go down as the top OK of the year and a big step forward on pancreatic cancer. And that is worth celebrating.
What is not going to be celebrated:
At close to $40K for a month's supply, $480K a year, I wonder if it's been priced for a pharma company looking to buy the company. Every leap forward in innovation is also another bucketload of financial toxicity for cancer patients who don't have the insurance they need to cover it all. That much further out of reach for way too many patients desperate to get it.
Living longer means paying more. How do you balance all that out? #FuckCancer #CancerSurvivor
endpoints.news/fda-approves-…
Innovative science. Financially toxic.
The FDA approval today of daraxonrasib will go down as the top OK of the year and a big step forward on pancreatic cancer. And that is worth celebrating.
What is not going to be celebrated:
At close to $40K for a month's supply, $480K a year, I wonder if it's been priced for a pharma company looking to buy the company. Every leap forward in innovation is also another bucketload of financial toxicity for cancer patients who don't have the insurance they need to cover it all. That much further out of reach for way too many patients desperate to get it.
Living longer means paying more. How do you balance all that out? #FuckCancer #CancerSurvivor
endpoints.news/fda-approves-…
Natasha Loder retweeted
The FDA approval today of daraxonrasib will go down as the top OK of the year and a big step forward on pancreatic cancer. And that is worth celebrating.
What is not going to be celebrated:
At close to $40K for a month's supply, $480K a year, I wonder if it's been priced for a pharma company looking to buy the company. Every leap forward in innovation is also another bucketload of financial toxicity for cancer patients who don't have the insurance they need to cover it all. That much further out of reach for way too many patients desperate to get it.
Living longer means paying more. How do you balance all that out? #FuckCancer #CancerSurvivor
endpoints.news/fda-approves-…
Natasha Loder retweeted
1/4 The most important story about Channel 4’s The Great ADHD Myth? may be what it has done to patients. In ADHD communities, people describe feeling distressed, angry and invalidated by a programme that presents their condition as unreal. #ADHD @ADHDUKcharity
Natasha Loder retweeted
Trial results for this new drug drew a standing ovation from scientists. Now approved in America, it nearly doubles median survival for certain types of advanced pancreatic cancer—breaking a decades-long deadlock against one of oncology’s deadliest targets economist.com/science-and-te…
